
    
      This is an observational, single-cohort, prospective study of systemic chemotherapy after
      CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab
      starting 4-16 weeks after surgery. CTRI Biostatistics Core personnel will assist in
      conducting analyses using the latest version of R (R Foundation for Statistical Computing,
      Vienna, Austria. http://www.R-project.org/).

      No therapy is included in this study. Subjects have already previously undergone surgery for
      their cancer. This study will observe the outcomes of the postoperative chemotherapy
      treatment the doctor chooses to treat the subject's cancer.
    
  